Clinical Trials Logo

Healthy clinical trials

View clinical trials related to Healthy.

Filter by:
  • Terminated  
  • Page 1 ·  Next »

NCT ID: NCT04811573 Terminated - Healthy Clinical Trials

A Study in Healthy People to Compare 3 Different Formulations of Apremilast Tablets Taken With or Without Food

Start date: March 31, 2021
Phase: Phase 1
Study type: Interventional

The aim of this trial is to establish bioequivalence between EU-, US- and Japan-sourced Otezla® tablet formulations to assure comparability of results from Phase III trials of BI 730357 (new oral agent for treatment of psoriasis as well as other T helper 17 cells (Th17)-mediated diseases) regardless of whether only the EU-sourced Otezla® or EU and US-sourced Otezla®/Japan-sourced Otezla® have been used as an active comparator.

NCT ID: NCT04575818 Terminated - Healthy Clinical Trials

A Study in Healthy Male Volunteers Investigating the Safety, Absorption and Elimination of Single Doses of GLPG4059

Start date: September 16, 2020
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of GLPG4059 in healthy volunteers after single oral administrations of GLPG4059 (SAD), compared to placebo (part 1). The effect of food (FE) (high-fat, high calorie) on the pharmacokinetics and relative bioavailability (rBA) of GLPG4059 will be assessed (part 2).

NCT ID: NCT04566926 Terminated - Healthy Clinical Trials

A Study of JNJ-64140284 in Healthy Male Participants

AMPAR
Start date: September 29, 2020
Phase: Phase 1
Study type: Interventional

The purpose of the study is to investigate and compare the pharmacokinetic (PK) profiles of a single dose of two solid dosage formulations of JNJ-64140284 in plasma and urine in healthy male participants under fed and fasting conditions; and to investigate the safety and tolerability of two solid dosage formulations of JNJ 64140284 versus placebo after single oral dose administration in healthy male participants under fed and fasting conditions in Part 1; to investigate the safety and tolerability of JNJ-64140284 versus placebo after single oral dose administration (or 1 divided dose, if applicable) (ascending dose levels) in healthy male participants; and to characterize the PK of a single dose (or 1 divided dose, if applicable) of JNJ-64140284 in plasma in healthy male participants in Part 2; and to investigate the effect of food on the PK of a single (or 1 divided dose, if applicable) therapeutic relevant dose of JNJ 64140284 in healthy male participants; and to investigate the safety and tolerability of JNJ-64140284 versus placebo after single oral dose administration at a therapeutic relevant dose (or 1 divided dose, if applicable) in fed conditions in Part 3.

NCT ID: NCT04556032 Terminated - Healthy Clinical Trials

Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women

Start date: September 9, 2020
Phase: N/A
Study type: Interventional

The objective of this study is to assess the effects of ergothioneine at two doses, compared to placebo, on cognition, mood, and sleep in healthy adult men and women.

NCT ID: NCT04540874 Terminated - Healthy Clinical Trials

A Study in Healthy Japanese Men to Test How Different Doses of BI 894416 Are Tolerated

Start date: October 5, 2020
Phase: Phase 1
Study type: Interventional

The objective of this trial is to investigate the safety, tolerability and pharmacokinetics of BI 894416 in healthy Japanese male subjects.

NCT ID: NCT04452006 Terminated - Healthy Clinical Trials

A Study in Healthy Subjects to Investigate the Safety and Tolerability of ACT- 541478 as Well as What ACT-541478 Does to the Body and the Way the Body Takes up, Distributes, and Gets Rid of ACT-541478

Start date: July 20, 2020
Phase: Phase 1
Study type: Interventional

A study in healthy subjects to investigate the safety and tolerability of ACT-541478 as well as what ACT-541478 does to the body and the way the body takes up, distributes, and gets rid of of ACT-541478

NCT ID: NCT04322227 Terminated - Healthy Clinical Trials

Study Investigating Effects of Foliglurax in Patients With Parkinson's Disease (PD) and Healthy Subjects

Start date: January 23, 2020
Phase: Phase 1
Study type: Interventional

The purpose of this study is to investigate effects of foliglurax on brain wave patterns (electric signals) in healthy subjects and in patients with PD

NCT ID: NCT04236453 Terminated - Healthy Clinical Trials

A Study in Healthy Participants to Assess the Effect of Darunavir, Emtricitabine, and Tenofovir Alafenamide in the Presence of Cobicistat When Administered as a Fixed Dose Combination (Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) Compared to the Co-administration of the Separate Agents

Start date: January 23, 2020
Phase: Phase 1
Study type: Interventional

The purpose of the study is to evaluate the single-dose pharmacokinetics (PK) and pivotal bioequivalence of 3 compounds Darunavir (DRV), emtricitabine (FTC), and tenofovir alafenamide (TAF) in the presence of cobicistat (COBI) when administered as an fixed dose combination (FDC) (Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide [D/C/F/TAF]) compared to the co-administration as the separate commercial formulations (DRV and F/TAF and COBI), under fed conditions, in healthy participants.

NCT ID: NCT04230122 Terminated - Healthy Clinical Trials

A Study of LY3478006 in Healthy Participants

Start date: February 17, 2020
Phase: Phase 1
Study type: Interventional

The purpose of this study is to learn more about how safe and how well tolerated LY3478006 is when given by injection into a vein or just under the skin to healthy participants. Blood tests will be done to check how much LY3478006 is in the bloodstream and how long the body takes to get rid of it. For each participant, the study will last up to about 16 weeks, including screening.

NCT ID: NCT04199585 Terminated - Healthy Clinical Trials

Safety and Tolerability of Lu AF95245 in Healthy Young Men

Start date: December 10, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this study is to investigate the safety and tolerability of Lu AF95245 and what the body does to Lu AF95245 after swallowing single doses of the drug